RLAY
Relay Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:48 UTC
Last close
18.03USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-26
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
-1800.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
-1536.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
0.06Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-06
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.10 against 0.38 on the market's range.
- Growth-28.6%31 of 100, below its sector
- Returns on capital-48.8%16 of 100, below its sector
- Margins-1971.6%4 of 100, below its sector
- Price5.6x10 of 100, below its sector
- Safety0.0693 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 2- Profit on each unit of sales-1,801%-4,612%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years-28.6%-25.3%Behind
Higher is better here.
- Debt against equity0.06n/an/a
Lower is better here.
- Gross marginn/an/an/a
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Xenon Pharmaceuticals Inc., RLAY is behind on 1 of 2 measures.
Against Xenon Pharmaceuticals Inc., RLAY is behind on 1 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales-1800.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
Sales growth over five years-28.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
Debt against equity0.06
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
Gross marginn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001193125-26-076739
- Reported in
- USD